异基因造血干细胞移植后5剂肺炎球菌疫苗接种方案的免疫原性
这项前瞻性队列研究纳入89例成人异基因造血干细胞移植受者,移植后4-6个月起接种4剂13价肺炎球菌结合疫苗(PCV13)和1剂23价肺炎球菌多糖疫苗(PPSV23),评估24种疫苗血清型的IgG抗体。基线未用免疫抑制治疗者总体血清保护率为47%(15/32),用免疫抑制治疗者为24%(11/46)(p=.03)。PCV13血清型应答尚可,但对PPSV23独有血清型应答差,导致总体应答不足。
要点
- 移植后4-6个月起接种5剂肺炎球菌疫苗方案:PCV13于T0、T1、T2、T8,PPSV23于T10。
- 基线未用免疫抑制治疗者总体血清保护率47%(15/32),用免疫抑制治疗者24%(11/46)(p=.03)。
- PCV13血清型血清保护率分别为78%和54%(p=.03),PPSV23独有血清型分别为28%和13%(p=.1)。
核心结论
- PCV13血清型免疫原性尚可,但对PPSV23独有血清型应答差,导致allo-HSCT受者肺炎球菌疫苗接种总体应答不足。
- 需要研究采用更高价次T细胞依赖性肺炎球菌疫苗的接种策略。
研究设计与样本
- 前瞻性队列研究,纳入89例成人异基因造血干细胞移植(allo-HSCT)受者进行最终分析。
- 移植后4-6个月起接种4剂PCV13(T0、T1、T2、T8)和1剂PPSV23(T10),T为入组后月数。
- 于T0、T4、T8、T10、T12采集血清,用免疫分析法检测全部24种疫苗血清型的IgG水平。
- 主要结局为T12时总体血清保护率,定义为24种疫苗血清型中17种IgG浓度≥1.3 μg/ml。
主要发现
- 总体血清保护率:基线未用免疫抑制治疗者47%(15/32) vs 用免疫抑制治疗者24%(11/46)(p=.03)。
- PCV13血清型血清保护率:未用免疫抑制治疗者78% vs 用免疫抑制治疗者54%(p=.03)。
- PPSV23独有血清型血清保护率:未用免疫抑制治疗者28% vs 用免疫抑制治疗者13%(p=.1)。
- 全部24种血清型的IgG浓度随时间显著升高。
关键数值与推荐
- 总体血清保护定义:24种疫苗血清型中17种IgG浓度≥1.3 μg/ml。
- PCV13于T0、T1、T2、T8接种,PPSV23于T10接种,T为入组后月数。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal schedule of pneumococcal vaccination after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. The objective of this study was to investigate the immunogenicity of a 5-dose pneumococcal vaccination schedule in adult allo-HSCT recipients with and without immunosuppressive therapy. In this prospective cohort study, allo-HSCT recipients received four doses of the 13-valent pneumococcal conjugate vaccine (PCV13) and one dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) starting 4-6 months after allo-HSCT. PCV13 was administered at T0, T1, T2, and T8 (T = months from enrollment) and PPSV23 at T10. Serum was collected at T0, T4, T8, T10, and T12, and IgG levels were measured for all 24 vaccine serotypes by immunoassay. The primary outcome was overall seroprotection at T12 defined as an IgG concentration ≥1.3 μg/ml for 17/24 vaccine serotypes in allo-HCST recipients with and without immunosuppressive therapy at baseline. Secondary outcomes were serotype-specific seroprotection and dynamics of IgG levels. We included 89 allo-HSCT recipients in the final analysis. Overall seroprotection was 47% (15/32) for patients without immunosuppressive therapy at baseline versus 24% (11/46) for patients with immunosuppressive therapy (p = .03). Seroprotection was higher for PCV13 serotypes (78% and 54% respectively; p = .03) and lower for PPSV23-unique serotypes (28% and 13% respectively; p = .1). IgG concentrations increased significantly over time for all 24 serotypes. Concluding, although immunogenicity of PCV13 serotypes was reasonable, the poor response to PPSV23 serotypes resulted in an insufficient overall response to pneumococcal vaccination for allo-HSCT recipients. Research into vaccination strategies with higher-valent T-cell-dependent pneumococcal vaccines is needed.
引用
- Garcia Garrido HM, Haggenburg S, Schoordijk MCE, et al. Immunogenicity of a 5-dose pneumococcal vaccination schedule following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2022. PMID: 35147238. doi:10.1002/ajh.26493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。